The article Hybrid
inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection was published in Scientific Reports (IF 5.52) on 7 March 2017.
A research was conducted by scientists from the Novel Dosage Laboratory, RASA Center at TPU, Pavlov First Saint Petersburg State Medical University, Research Institute of Influenza of Ministry of Healthcare of the Russian Federation and Queen Mary University of London School of Engineering and Materials Science. Scientists from Gorbacheva Research Institute of Pediatric Hematology and Transplantation also took an active part in the research.
A new method to fight influenza A (H1N1) virus is focused on training our body to produce interferons (proteins that make our body immune to the virus) faster.
TPU scientists suggest activating cell immune system with hybrid spherical microcontainers that contain antiviral RNAs (Ribonucleic Acids).
«We used small interfering RNA, which interact with matrix RNA (mRNA) of the influenza virus. This leads to degradation of «viral» RNA, preventing its translation on ribosomes into a protein encoded by it, thereby reducing the viral gene expression," says one of the main
The delivery of microcontainers with small interfering RNA is ensured within the human body through respiratory tract — nasal sinuses. In the sinus cavity the microcontainers degrade and release RNA into cells, which results in the transfection and therefore enhances immunity against influenza virus.
«For the first time we have developed an approach of efficient matrix RNA delivery through encapsulation into new hybrid microcarriers obtained by integration of LbL technique and
According to scientists, the first laboratory test showed that such interaction results in an 80% drop of virus proteins.
